Market Snapshot
  • U.S.
  • Europe
  • Asia
Ticker Volume Price Price Delta
DJIA 16,421.89 13.35 0.08%
S&P 500 1,864.85 2.54 0.14%
NASDAQ 4,101.28 5.77 0.14%
Ticker Volume Price Price Delta
STOXX 50 3,155.81 16.55 0.53%
FTSE 100 6,625.25 41.08 0.62%
DAX 9,409.71 91.89 0.99%
Ticker Volume Price Price Delta
NIKKEI 14,512.38 -3.89 -0.03%
TOPIX 1,171.40 -1.97 -0.17%
HANG SENG 22,760.24 64.23 0.28%

Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses In Excess Of $100,000 Investing In Ventrus Biosciences, Inc. To



  Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses In Excess Of
     $100,000 Investing In Ventrus Biosciences, Inc. To Contact The Firm

PR Newswire

NEW YORK, May 18, 2013

NEW YORK, May 18, 2013 /PRNewswire/ -- Faruqi & Faruqi, LLP, a leading
national securities law firm, is investigating potential securities fraud at
Ventrus Biosciences, Inc. ("Ventrus" or the "Company") (NASDAQ: VTUS).

(Logo: http://photos.prnewswire.com/prnh/20120119/MM38856LOGO)

The investigation focuses on whether the Company and its executives violated
federal securities laws by issuing false and/or misleading statements and
failing to disclose materially adverse facts concerning the Company's lead
product iferanserin (VEN 309) ("VEN 309").

The Company described VEN 309 as a new chemical entity for the topical
treatment of symptomatic internal hemorrhoids.  According to Ventrus, VEN 309
demonstrated good tolerability and no severe adverse events while showing
statistically significant improvements in bleeding, itchiness, and pain in
seven clinical studies between 1993 and 2003.  Moreover, the Company touted
that the prior results from Phase II trials of VEN 309 demonstrated the
product's clinical efficacy.

However, Ventrus issued a press release on June 25, 2012 announcing that VEN
309 failed its Phase III trial, causing the Company to abandon further
development of VEN 309, including any further attempt to obtain FDA approval.
 In response to this news, the price of Ventrus common stock plummeted over
50%, to $5.02 per share, on June 25, 2012.

Request more information now by clicking here:  www.faruqilaw.com/VTUS.  There
is no cost or obligation to you.

Take Action

If you invested in Ventrus stock or options between December 17, 2010 and June
25, 2012 and would like to discuss your legal rights, visit
www.faruqilaw.com/VTUS.  You can also contact us by calling Richard Gonnello
or Francis McConville toll free at 877-247-4292 or at 212-983-9330 or by
sending an e-mail to rgonnello@faruqilaw.com or fmcconville@faruqilaw.com. 
Faruqi & Faruqi, LLP also encourages anyone with information regarding
Ventrus' conduct to contact the firm, including whistleblowers, former
employees, shareholders and others.

Attorney Advertising.  The law firm responsible for this advertisement is
Faruqi & Faruqi, LLP (www.faruqilaw.com).  Prior results do not guarantee or
predict a similar outcome with respect to any future matter.  We welcome the
opportunity to discuss your particular case.  All communications will be
treated in a confidential manner.

FARUQI & FARUQI, LLP
369 Lexington Avenue, 10th Floor
New York, NY 10017
Attn:  Richard Gonnello, Esq.
rgonnello@faruqilaw.com
Francis McConville, Esq.
fmcconville@faruqilaw.com
Telephone: (877) 247-4292 or (212) 983-9330

 

SOURCE Faruqi & Faruqi, LLP

Website: www.faruqilaw.com
Sponsored Links
Advertisement
Advertisements
Sponsored Links
Advertisement